ARTICLE | Company News

Biotie neurology news

November 15, 2010 8:00 AM UTC

Biotie spun out newco biocrea GmbH (Radebeul, Germany) to focus on developing phosphodiesterase (PDE) inhibitors to treat CNS disorders. Biotie granted biocrea rights to three PDE inhibitors which are planned to reach the clinic by 2012. PDE10, a PDE-10 inhibitor, is in preclinical trials to treat schizophrenia. Thomas Kronbach, formerly CSO at Biotie, has been appointed CEO of the newco. ...